- Home
- SERA vs ANVS Comparison
SERA vs ANVS Comparison
Compare SERA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SERA | ANVS |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 69.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SERA | ANVS |
|---|---|---|
| Price | $2.29 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 62.4K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.32 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,000.00 | N/A |
| Revenue This Year | $554.81 | N/A |
| Revenue Next Year | $517.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.19 | N/A |
| 52 Week Low | $1.37 | $1.54 |
| 52 Week High | $4.09 | $5.50 |
Technical Indicators
Market Signals| Indicator | SERA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 44.61 |
| Support Level | $1.67 | $1.79 |
| Resistance Level | $2.40 | $2.38 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 84.63 | 22.83 |
Price Performance
Historical ComparisonAbout SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.